Breast Cancer Clinical Trial
— OPTICOACHOfficial title:
Randomized and Prospective Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast Cancer
Verified date | January 2024 |
Source | Institut Curie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Evaluate the impact of coaching sessions on the return to work rate (number of patients returning at work / total number of patients per arm) 6 months after inclusion in the study for breast cancer in professionnally active patients.
Status | Terminated |
Enrollment | 69 |
Est. completion date | March 8, 2024 |
Est. primary completion date | June 15, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: Any patient active at the time of the diagnosis of breast cancer, treated consecutively at the Institut Curie during the study period, and whose first treatment will be surgery, will be offered participation in the study. 1. Invasive non-metastatic breast cancer, treated first by surgery 2. Age = 18 and = 60 years 3. Active woman at the time of diagnosis 4. Patient with internet access and email address 5. Patient affiliated with a social security scheme, speaking and reading French 6. Signature of informed consent Exclusion Criteria: 1. In situ breast cancer 2. History of breast cancer 3. Metastatic breast cancer 4. Inflammatory Breast Cancer 5. Woman with a life expectancy <6 months at the time of diagnosis (in relation to other serious chronic diseases) 6. Persons deprived of liberty or under guardianship 7. Impossibility to submit to the medical follow-up of the test for geographical, social or psychological reasons |
Country | Name | City | State |
---|---|---|---|
France | Institut Curie | Paris | |
France | Institut Curie | Saint-Cloud |
Lead Sponsor | Collaborator |
---|---|
Institut Curie |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Impact of coaching sessions on the return to work rate (number of patients returning at work / total number of patients per arm) 6 months after inclusion in the study | The rate of patients returning to work (part-time or full-time) for more than 2 weeks to 6 months of inclusion in the study in each group. | 6 months | |
Secondary | Quality of the return to work | Evaluation of the quality of the return to work at 6 and 12 months after inclusion by questionnaire VOW / QFT (in case of return to work only).
Evaluation scale : 1=never to 4=ever |
6 and 12 months | |
Secondary | Sustainability of the return to work | Evaluation of the durability of the return to work at 6 and 12 months after inclusion by registration by the patients of the number of days off work and / or working time arrangement | 6 and 12 months | |
Secondary | Impact of the return to work / work stoppage on the quality of life | Evaluation of the impact of return to work / work stoppage on the quality of life estimated by QLQ-C30 questionnaire at baseline and at 6 and 12 months post-inclusion | 6 and 12 months | |
Secondary | The production losses related to presenteeism during maintenance or return to work | Evaluation of production losses related to presenteeism at the time of maintenance or return to work at 6 and 12 months post inclusion, by collecting the number of days worked during the study period (12 months) | 6 and 12 months | |
Secondary | The production losses related to presenteeism during maintenance or return to work | Evaluation of the loss of productivity during a professional activity : in case of return to work, the "Work limitation questionnaire" will be completed at 6 and 12 months after inclusion | 6 and 12 months | |
Secondary | The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) | Determining the determinants of return to work at 6 and 12 months post inclusion using the QLQ-BR23questionnaire.
Evaluation scale : 0=not at all to 4=a lot |
12 months | |
Secondary | The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) | Determining the determinants of return to work at 6 and 12 months post inclusion using the QLQ-FA12 questionnaire.
Evaluation scale : 0=not at all to 4=a lot |
6 and 12 months | |
Secondary | The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) | Determining the determinants of return to work at 6 and 12 months post inclusion using the HADS questionnaire.
Anxiety scale : 3=most of the time to 0=never Depression scale : 3=never to 0= most of the time |
6 and 12 months | |
Secondary | The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) | Determining the determinants of return to work at 6 and 12 months post inclusion using the SSQ6 questionnaire.
Evaluation scale : 1=really dissatisfied to 6 =really satisfied |
6 and 12 months | |
Secondary | The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) | Determining the determinants of return to work at 6 and 12 months post inclusion using the Brief Cope questionnaire.
Evaluation scale : 0=not at all to 4=absolutely |
6 and 12 months | |
Secondary | The determinants of return to work (factors associated with a return to work "successful": early, sustainable and quality) | These determinants will also be evaluated through the collection of socio-demographic data, cancer characteristics and treatments administered. | 6 and 12 months | |
Secondary | The medico-economic impact of returning to work | Evaluation of the medico-economic impact of return to work by comparing the costs of care in the two groups | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |